secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001104659-26-002323
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reaffirms FY2025 revenue guidance of $250-300M; cash $307M as of Q3
---------------------------------------------------------------------------

- Expects to achieve previously disclosed FY2025 revenue guidance of $250-300M in first full year of Amtagvi sales.
- Cash position of $307M as of 9/30/25, expected to fund operations into Q2 2027.
- 85 authorized treatment centers as of 12/31/25; over 1,000 patients treated with commercial and clinical TIL products.
- Gross margin of 43% in Q3 2025; organization streamlined in Q3 2025 to support improved margins.
- IOV-LUN-202 NSCLC trial enrollment complete; data update expected in 2026 with potential launch in H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926002323/0001104659-26-002323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926002323/tm262669d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer